PMID- 33504577
OWN - NLM
STAT- MEDLINE
DCOM- 20210831
LR  - 20210831
IS  - 2056-5933 (Electronic)
IS  - 2056-5933 (Linking)
VI  - 7
IP  - 1
DP  - 2021 Jan
TI  - Effect of significant weight loss on disease activity: reason to implement this 
      non-pharmaceutical intervention in daily clinical practice.
LID - 10.1136/rmdopen-2020-001498 [doi]
LID - e001498
AB  - Obesity is very common in patients with inflammatory rheumatic diseases (IRDs), 
      of which between 27% and 37% of patients have a body mass index >/=30 kg/m(2) In 
      addition to further increasing the risk of developing cardiovascular diseases 
      (CVDs) in this group of patients, obesity is associated with higher disease 
      activity and a lower response to drug therapy. This case series showed that in 
      those patients with rheumatoid arthritis or psoriatic arthritis with a 
      substantial weight loss of >10% of body mass, median Disease Activity Score 28 
      joints score decreased with 0.9. This reduction in disease activity resulted in 
      an increase in the percentage of patients achieving remission from 6% to 63%. 
      This reduction in disease activity was obtained without intensification of 
      medical treatment in 87% of the patients. This case series supports the current 
      evidence that weight reduction has positive effects on the course of the disease 
      and thus also on the CVD risk profile in these patients. Therefore, weight loss 
      can serve as a non-pharmacological treatment option in obese patients with IRDs.
CI  - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Weijers, Julia M
AU  - Weijers JM
AUID- ORCID: 0000-0001-9756-9639
AD  - Department of IQ Healthcare, Radboudumc, Nijmegen, Netherlands 
      julia.weijers@radboudumc.nl.
FAU - Muskens, Wieland D
AU  - Muskens WD
AD  - Department of IQ Healthcare, Radboudumc, Nijmegen, Netherlands.
FAU - van Riel, Piet L C M
AU  - van Riel PLCM
AD  - Department of IQ Healthcare, Radboudumc, Nijmegen, Netherlands.
AD  - Department of Rheumatology, Ziekenhuis Bernhoven, Uden, Netherlands.
LA  - eng
PT  - Journal Article
PL  - England
TA  - RMD Open
JT  - RMD open
JID - 101662038
SB  - IM
MH  - *Arthritis, Psoriatic/drug therapy
MH  - *Arthritis, Rheumatoid/complications/drug therapy
MH  - Body Mass Index
MH  - Humans
MH  - Obesity/complications/therapy
MH  - Weight Loss
PMC - PMC7843325
OTO - NOTNLM
OT  - arthritis
OT  - cardiovascular diseases
OT  - psoriatic
OT  - rheumatoid
COIS- Competing interests: None declared.
EDAT- 2021/01/29 06:00
MHDA- 2021/09/01 06:00
PMCR- 2021/01/27
CRDT- 2021/01/28 05:33
PHST- 2020/10/28 00:00 [received]
PHST- 2021/01/13 00:00 [revised]
PHST- 2021/01/14 00:00 [accepted]
PHST- 2021/01/28 05:33 [entrez]
PHST- 2021/01/29 06:00 [pubmed]
PHST- 2021/09/01 06:00 [medline]
PHST- 2021/01/27 00:00 [pmc-release]
AID - rmdopen-2020-001498 [pii]
AID - 10.1136/rmdopen-2020-001498 [doi]
PST - ppublish
SO  - RMD Open. 2021 Jan;7(1):e001498. doi: 10.1136/rmdopen-2020-001498.